Merck reports a hit and a miss with anti-TL1A Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 4 August, 2026

One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.

presented by Why Amer­i­ca's med­i­cine be­came a na­tion­al se­cu­ri­ty ques­tion

SPOTLIGHT Live today at 11 am ET: Who wants an AstraZeneca-Bristol Myers megadeal? •  AstraZeneca-Bristol Myers megamerger talk leaves Wall Street wanting more answers

news Pfizer to make $2.5B in new cost cuts Exclusive: Pathos AI signs two deals, plans to raise Series E at $3B valuation Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in a rare lung disease Bayer eyes German launch of stroke drug despite spending cuts in the country In Focus Work ethic becomes a flashpoint as China's biotech pace quickens

Aug 19 1:00 pm ET From pilots to production: AI across R&D, safety, regulatory, and clinical sponsored by IBM Aug 27 12:00 pm ET Same molecule, different paths: Where value goes in cross-border dealmaking in a new era sponsored by PharmCube Sep 03 11:00 am ET How leading pharma organizations are putting AI agents to work sponsored by Medable

Scientist, Drug Discovery Data for AI/ML D. E. Shaw Research New York, NY, USA Machine Learning Researchers and Engineers D. E. Shaw Research New York, NY, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The China biotech story is moving fast. On Aug. 6, Endpoints hosts debate-style panels on how China's rise is forcing biotech to rethink innovation, live in Boston. Space is limited. Reserve your spot now.

ENDPOINTS PHARMA RFK Jr. interview sparks corrections on vaccines, pandemics and measles News Briefing Curium buys Lantheus for $8B; Sandoz settles price-fixing cases BioNTech names Sobi's Guido Oelkers as incoming CEO

in case you missed it 1. Update: Supernus, Indivior to merge and form CNS-focused drugmaker 2.